Europe blesses new BMS, Pfizer clotbuster; With HIV approval, J&J anticipates $9B in new drugs;

Bristol-Myers Squibb building

@FiercePharma: Pharma bosses love iPads, but some reps are skeptical. News | Follow @FiercePharma

> European regulators approved a potentially lucrative medicine from Bristol-Myers Squibb and Pfizer, Eliquis, for prevention of blood clots in patients who have undergone hip or knee replacement surgery. Item

> Pfizer's cancer drug Sutent won U.S. approval to treat a rare form of pancreatic cancer known as pancreatic NET. Report

Whitepaper

Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

> Johnson & Johnson, which won approval last week for the first new AIDS medicine since 2008, plans to introduce four drugs this year that may combine for annual sales of $9 billion, helping to offset product recalls and declining profit for medical devices. Story

> Cephalon said a U.S. district court judge granted its request for a restraining order barring Mylan from launching a generic version of the muscle relaxant Amrix. News

> Bayer is looking for a speedy remedy for stagnant aspirin sales with a new form of the pain reliever that works in half the time.

> Acorda Therapeutics stock gained 14 percent Friday after European regulators backed its Fampyra drug for improving walking in multiple sclerosis patients. Story

> Google was warned repeatedly by a group of state regulators and industry watchdogs that many of the online drugstores advertising on its network were violating U.S. laws, the Wall Street Journal reports. News

> Targacept said it will price its public offering of more than 3.7 million shares at a $20.50 per share. Report

Biotech News

@FierceBiotech: ASCO highlights targeted cancer drugs from Pfizer, Exelixis. Report | Follow @FierceBiotech

@JohnCFierce: We've had quite a spate of approvals so far this year. Maybe I can wrap this year without another look at appalling productivity. | Follow @JohnCFierce

> FDA approves Vertex hep C drug Incivek. Story

> Sanofi's Zerhouni drops biotech model in favor of "open innovation." News

> J&J is on a roll as drug deals deliver blockbuster approvals. Article

Biotech IT News

> Clinipace Worldwide scoops up Swiss competitor. Report

> New software aids in discovery of cancer gene fusions. Item

> PRA International buys Kinship to boost eClinical software offerings. News

> NIH pumping $23M into data center and computer analyses of genomes. Report

> Algorithms mine articles to predict bad drug reactions. Story

Medical Device News

> Device groups sign global compliance pact. Story

> Panel: Investing in device start-ups has gotten riskier. Report

> FDA clears test for disease affecting military personnel. Article

> Novate Medical raises $12.4M investment. Piece

And Finally... Florida's Department of Juvenile Justice has continued giving children antipsychotic pills despite a series of lawsuits filed against the drugs' makers in the past three years. Report

Read more on

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.